Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 21, 2026
RBB Bancorp (RBB) Delivers Q2 Net Income of $10.1 Million and EPS Beat

RBB Bancorp (RBB) Delivers Q2 Net Income of $10.1 Million and EPS Beat

Key Takeaways

  • RBB Bancorp reported net income of $10.1 million for the second quarter ended June 30, 2026.
  • Diluted earnings per share reached $0.59, exceeding the consensus estimate of $0.52.
  • Results reflect solid credit quality improvements that helped offset softer revenue trends.
  • The company announced a new $1 million share repurchase program.
  • EPS growth highlights resilience in core banking operations amid regional market conditions.

Earnings Context and Why It Matters

RBB Bancorp operates as the holding company for Royal Business Bank, serving Asian-centric communities with commercial and consumer banking services. The second quarter results arrive after a period of steady performance in prior quarters, with investors closely monitoring net interest income trends, loan growth, and asset quality in the regional banking sector. Earnings reports like this provide key signals on deposit costs, lending demand, and overall profitability in a fluctuating interest rate environment.

Reported Results

RBB Bancorp posted net income of $10.1 million, or $0.59 diluted earnings per share, for the quarter ended June 30, 2026. This outperformed analyst expectations of approximately $0.52 per share. Revenue trends showed some softness, but credit quality gains provided support. The company also introduced a $1 million share buyback authorization, signaling confidence in its capital position. Key operating metrics remained generally in line with recent trends, with no major surprises in noninterest expenses or provisions for credit losses. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction and Investor Sentiment

Following the release, shares of RBB Bancorp experienced modest movement as investors digested the earnings beat and buyback announcement. Sentiment heading into the report had been cautiously optimistic, with analysts noting the bank’s focus on niche markets. Post-earnings trading reflected a measured response, with attention turning to forward guidance and balance sheet positioning rather than dramatic price swings.

AI Tools in Portfolio Monitoring

One thing that stands out when reviewing quarterly results like these is how AI-driven platforms can help surface comparable names and track patterns across the sector. I often turn to Tickeron’s AI Screener for this kind of work because it allows quick filtering by fundamentals, technical signals, and industry metrics. AI Screener Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. From what I see, this kind of tool fits naturally into a routine review of bank earnings without replacing traditional analysis.

Forward Outlook and Key Factors to Monitor

Investors will focus on net interest margin trends as interest rates evolve and deposit competition persists. Loan origination volumes in commercial real estate and small business segments remain key indicators of growth potential. Credit quality metrics, including nonperforming assets and net charge-offs, warrant ongoing attention given the regional banking landscape.

The new share repurchase program could support earnings per share over coming quarters if executed. Management commentary on expense control and digital banking initiatives may provide additional color on efficiency efforts. Broader industry dynamics, such as regulatory developments and economic conditions in California and Hawaii markets, will also influence performance.

Upcoming catalysts include third-quarter results and any updates on capital allocation strategies. Monitoring these elements will help assess the sustainability of recent profitability levels.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RBB

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


RBB sees MACD Histogram crosses below signal line

RBB saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 08, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for RBB moved out of overbought territory on July 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RBB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 04, 2026. You may want to consider a long position or call options on RBB as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RBB advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 208 cases where RBB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RBB's P/B Ratio (0.851) is slightly lower than the industry average of (1.356). P/E Ratio (11.029) is within average values for comparable stocks, (24.445). RBB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.896). Dividend Yield (0.024) settles around the average of (0.031) among similar stocks. P/S Ratio (3.470) is also within normal values, averaging (3.864).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RBB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RBB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 56, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are PNC Financial Services Group (NYSE:PNC), US Bancorp (NYSE:USB), Itau Unibanco Banco Holding SA (NYSE:ITUB), Deutsche Bank Aktiengesellschaft (NYSE:DB), Banco Bradesco SA (NYSE:BBD), Huntington Bancshares (NASDAQ:HBAN), Regions Financial Corp (NYSE:RF), KeyCorp (NYSE:KEY).

Industry description

Regional banks have a smaller reach than major banks, and cater mostly to one region of a country, such as a state or within a group of states. They offer services often similar – albeit with some limitations/smaller scale – compared to major banks. Taking deposits, making loans, mortgages, leases, credit cards , fund management, insurance and investment banking. SunTrust Banks, State Street Corp., M&T Bank Corp. are some examples of U.S. regional banks.

Market Cap

The average market capitalization across the Regional Banks Industry is 6.57B. The market cap for tickers in the group ranges from 10.73K to 142.82B. CIHHF holds the highest valuation in this group at 142.82B. The lowest valued company is ACBCQ at 10.73K.

High and low price notable news

The average weekly price growth across all stocks in the Regional Banks Industry was 1%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 10%. OPHC experienced the highest price growth at 28%, while BCBP experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Regional Banks Industry was -2%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 46
SMR Rating: 53
Profit Risk Rating: 55
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
RBB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a regional bank

Industry RegionalBanks

Profile
Details
Industry
Regional Banks
Address
1055 Wilshire Boulevard
Phone
+1 213 627-9888
Employees
369
Web
https://www.royalbusinessbankusa.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.